EncephalX Inc.

Based in Canada, EncephalX provides innovative solutions in the field of neurosurgery, focusing on the development of advanced cranial implants for patients with traumatic brain injuries or strokes. EncephalX, founded in 2020 and headquartered in Sherbrooke, Canada, specializes in innovative medical technology with a focus on dynamic cranial implants. The company was founded by its CEO Simon Lapointe, who has a background in technology and healthcare. In January 2026, EncephalX raised CAD 2.

25 million in a funding round led by ACET Capital, along with participation from Investment Quebec, AQC Capital, and Halo Health, Inc. EncephalX specializes in the development of dynamic cranial implants, particularly through its Dynamic Cranioplasty System (DCPS). This innovative product addresses the needs of patients suffering from traumatic brain injuries or strokes, offering a safer and more efficient cranioplasty solution. The DCPS reduces recovery time by streamlining the surgical process, requiring only a single procedure instead of the traditional two.

Its primary clients include hospitals and surgical centers focused on neurosurgical treatments, particularly in North America and Europe, where the demand for such solutions is significant. EncephalX's revenue model is based on direct sales of its dynamic cranial implants to healthcare facilities that perform neurosurgical procedures. The flagship product, the Dynamic Cranioplasty System, will be marketed through partnerships with hospitals and surgical centers, with transactions executed on a per-implant basis. These sales are structured as B2B, where healthcare providers procure the products for surgical use, potentially allowing for premium pricing due to the unique benefits offered by the technology, including reduced complication rates and improved recovery times.

EncephalX plans to utilize the recent funding of CAD 2. 25 million raised in January 2026 to complete initial human testing and support the regulatory submission process for its surgical device. The company is also looking to expand its offerings into international markets, focusing specifically on North America and Europe by the end of 2026. New products are in development, aimed at further enhancing its portfolio and addressing broader patient needs in neurosurgery.